Rolph, Tim
https://orcid.org/0000-0001-5284-6903
Mayo Clinic
Department of Research and Development, Akero Therapeutics, San Francisco, CA, USA
Citations 1
Fibroblast growth factor (FGF)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (NAFLD)?
Ritchie, Michael M., Hanouneh, Ibrahim A., Noureddin, Mazen , Rolph, Tim , Alkhouri, Naim
Expert Opinion on Investigational Drugs | January 17, 2020 | Volume: 29 | Issue: 2 | Pages: 197-204
